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ABSTRACT
Mutations in the dysferlin gene lead to limb girdle
muscular dystrophy 2B, Miyoshi myopathy and distal
anterior compartment myopathy. A cohort of 36 patients
affected by dysferlinopathy is described, in the ﬁrst UK
study of clinical, genetic, pathological and biochemical
data. The diagnosis was established by reduction of
dysferlin in the muscle biopsy and subsequent mutational
analysis of the dysferlin gene. Seventeen mutations were
novel; the majority of mutations were small deletions/
insertions, and no mutational hotspots were identiﬁed.
Sixty-one per cent of patients (22 patients) initially
presented with limb girdle muscular dystrophy 2B, 31%
(11 patients) with a Miyoshi phenotype, one patient with
proximodistal mode of onset, one patient with muscle
stiffness after exercise and one patient as
a symptomatic carrier. A wider range of age of onset
was noted than previously reported, with 25% of
patients having ﬁrst symptoms before the age of
13 years. Independent of the initial mode of presentation,
in our cohort of patients the gastrocnemius muscle was
the most severely affected muscle leading to an inability
to stand on tiptoes, and lower limbs were affected more
severely than upper limbs. As previous anecdotal
evidence on patients affected by dysferlinopathy
suggests good muscle prowess before onset of
symptoms, we also investigated pre-symptomatic ﬁtness
levels of the patients. Fifty-three per cent of the patients
were very active and sporty before the onset of
symptoms which makes the clinical course of
dysferlinopathy unusual within the different forms of
muscular dystrophy and provides a challenge to
understanding the underlying pathomechanisms in this
disease.
INTRODUCTION
Ten years ago the dysferlin gene was cloned and
identiﬁed as the gene mutated in limb girdle
muscular dystrophy (LGMD) 2B, and Miyoshi
myopathy (MM).
1 2 While LGMD2B is charac-
terised by proximal muscle involvement, patients
affected by MM present with distal muscle weak-
ness at onset.
12Subsequently, distal anterior
compartment myopathy and a proximodistal mode
of onset have been described as further phenotypes/
modes of presentation in dysferlin deﬁciency,
3e5
and some patients have been reported with hyper-
CKaemia.
5 During the course of the disease, the
phenotypes show a considerable amount of overlap
so that weakness may extend from proximal to
distal muscle groups and vice versa.
46The factors
responsible for these distinct patterns of presenta-
tion are unknown. Therefore, further character-
isation of patients with dysferlin deﬁciency may
help to identify possible distinct features within
this entity and might provide clues to underlying
pathogenetic mechanisms.
7
Dysferlin deﬁcient muscular dystrophy is
inherited as an autosomal recessive trait, age of
onset has been found to be usually young adult-
hood and the progression to be slow.
4 68Overt
cardiac pathology appears not to be a common
ﬁnding in most patients.
46However, cardiac
impairment in dysferlin deﬁciency under stress has
been shown in the knockout mouse,
9 and two
studies have demonstrated dilated cardiomyopathy
in a total of six patients with dysferlinopathy.
10 11
Dysferlin is a 230 kDa transmembrane protein and
has been shown to be involved in the process of
membrane repair,
12 myoblast differentiation,
13
T tubulogenesis
14 15 and muscle regeneration,
16
most likely through mechanisms of membrane
organisation. So far this has not been proven but
the hypothesis is based on the following ﬁndings:
the biochemical structure of dysferlin with six C2
domains which are calcium sensitive domains
involved in fusion and trafﬁcking of membranes,
the homology to fer-1 in C elegans and otoferlin,
both proteins important for vesicle fusion, an
upregulation of proteins involved in vesicle traf-
ﬁcking,
17 a subsarcolemmal accumulation of vesi-
cles below the surface of dysferlin deﬁcient
myoﬁbres
18 and altered T tubule morphology and
orientation on the ultrastructural level.
15 Recent
evidence also suggests a role for dysferlin in
monocyte phagocytosis.
19
A unique ﬁnding within the spectrum of
muscular dystrophies is that the majority of
patients with dysferlin deﬁciency appear to have
good muscle strength before onset of symptoms
leading to good performance at sports or to the
ability to cope well with physically demanding jobs
although this is suggested by mainly anecdotal
evidence.
19 20 This observation contradicts the
clinical course of other muscular dystrophies (MDs)
where the majority of patients describe some sort
of impaired muscle function before onset of overt
weakness. This aspect is difﬁcult to address, has not
yet been formally assessed but may be a distinct
feature in dysferlin deﬁciency. In this ﬁrst study on
the clinical spectrum of dysferlinopathy in the UK,
we present clinical, genetic, pathology and
biochemical data on patients with dysferlinopathy,
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levels.
MATERIALS AND METHODS
Thirty-six patients with dysferlin deﬁciency from 32 families
were assessed retrospectively. The diagnosis of dysferlinopathy
was made based on reduction or absence of dysferlin in the
muscle biopsy and mutation analysis. Patients were referred to
the Newcastle Muscle Centre as part of the National Commis-
sioning Group designated specialised diagnostic service for
LGMDs in the UK for examination and further evaluation.
During the clinic visits a complete history and family history
were taken, and patients were speciﬁcally asked about their
muscle strength and athletic performance before onset of
symptoms, such as their performance at school sports. A
detailed muscle assessment was undertaken by the same
examiner in 21 patients, and muscle strength scored.
21
Immunoanalysis of muscle biopsies
Muscle biopsies were analysed as part of the National
Commissioning Group designated specialised diagnostic service
for LGMD. Optimised immunohistochemical and multiplex
western blot protocols were used for the demonstration and
resolution of muscular dystrophy associated proteins, as previ-
ously described.
22 23 Primary antibodies used for immunohisto-
chemistry were directed against: b-spectrin (RBC2/3D5),
b-dystroglycan (43DAG/8D5), C terminus dystrophin (Dy8/
6C5) and N terminus dystrophin (Dy10/12B2), a-sarcoglycan
(Ad1/20A6), b-sarcoglycan (1/5B1), g-sarcoglycan (35DAG/
21B5), d-sarcoglycan (3/12C1) (all from Novocastra, Newcastle,
UK) and caveolin-3 (Transduction Laboratories, Oxford, UK).
Antibodies used for western blotting were: anti-dysferlin (NCL-
hamlet exon 53), anti-dystrophin (Dy8/6C5 C-terminus and
Dy4/6D3 rod domain), anti-a-sarcoglycan, anti-b-dystroglycan,
anti-g-sarcoglycan, anti-calpain 3 (NCL-CALP-2C4 and NCL-
CALP-12A2) and anti-caveolin 3 (Transduction Laboratories).
Myosin heavy chain staining on the post-blotted gel was used as
loading control.
Evaluation of biopsies
Two independent raters, experienced in reading of muscle biop-
sies and western blots, evaluated the biopsies (LK, AA). Protein
expression on sections and blots was scored as normal +++,
slight reduction ++, reduction +, severe reduction 6 and
absence  . b Spectrin was used as a marker of membrane
integrity on immunohistochemistry.
Sequencing
Sequencing analysis was performed using bidirectional ﬂuores-
cent sequencing of all 55 exons of the dysferlin gene either in
Newcastle upon Tyne (Institute of Human Genetics) or in
Würzburg (central sequencing facility of the MD-NET, Institute
of Human Genetics, University of Würzburg, Germany).
Twenty-two patients with a molecular diagnosis of LGMD2A
(Newcastle Muscle Centre) were used as a control group for the
assessment of pre-symptomatic ﬁtness levels in dysferlin deﬁ-
cient patients. In these patients, molecular diagnosis had been
established via bidirectional ﬂuorescent sequencing of all 24
exons of the calpain 3 gene in Newcastle upon Tyne, UK.
Muscle assessment
Assessment of muscle strength was conducted by one experi-
enced evaluator (ME). Muscle groups that were examined were
those that produced neck ﬂexion and extension, shoulder
abduction, ﬂexion, horizontal adduction, elbow ﬂexion including
brachioradialis and biceps, elbow extension, wrist ﬂexion and
extension, ﬁnger ﬂexion and extension. In the lower limb, hip
ﬂexion, extension, abduction and adduction, knee ﬂexion and
extension and in the ankle plantarﬂexion, dorsiﬂexion, inversion
and eversion. Each muscle group was assessed in several different
positions to determine antigravity activity as well as the ability
to resist a manually applied force. Strength was graded using an
11 point scale from 5 (normal strength) to 0 (no activity). The
same order of assessment was followed in each case. Each
patient was also asked to demonstrate their ability to stand on
tiptoes as manual resistance cannot sufﬁciently demonstrate
normal strength plantarﬂexion.
Upper and lower limb score
Muscles of the upper or lower limb were scored on an 11 point
numerical scale (0e10) according to the strength grade (also 11
point). The score of the patient was calculated as the per cent of
the maximum score achievable.
Statistical analysis
Fisher’s exact test for count and the Student’s t test were
applied. Statistical signiﬁcance was established when p<0.05.
RESULTS
Muscle immunoanalysis ﬁndings
Immunohistochemistry
Dysferlin was either severely reduced or absent on tissue
sections with no apparent correlation to the clinical presentation
or underlying mutation. b-dystroglycan was reduced in 17% of
samples, and caveolin-3 showed reduced sarcolemmal labelling
in 25% of cases. No correlation was found between the residual
labelling and the phenotype of the patient.
Western blot
Dysferlin bands were reduced or absent in all patients. Neither
the type of mutation nor the phenotype at presentation showed
a correlation to the amount of dysferlin detectable on blots.
Similar to previously reported data,
24 25 we found a secondary
reduction of calpain 3 in the majority of patients (77% exon 1,
82% exon 8) and a more variable reduction of caveolin-3 (67% in
12 blots probed with anti-Cav-3).
Correlation of phenotype (MM vs LGMD) with inﬂammation in the
muscle biopsy
There was no correlation between the phenotype and the level
of inﬂammation in the muscle biopsy identiﬁed by haematox-
ylineeosin staining.
Mutation analysis
Molecular diagnosis was established in all patients with 89% (32
patients) harbouring two mutations in the dysferlin gene: 14
patients were homozygous (including one patient with an
additional heterozygous mutation) and 18 patients were
compound heterozygous. One of the latter patients had three
mutations (patient No 13). In 11% (four patients), only one
mutation was detected, including one patient who is likely to be
a symptomatic carrier. The patients with one mutation only
were included on the basis of dysferlin depletion in the muscle
biopsy. A summary of the mutations found in our patient
cohort, the percentage of different mutations and their location
within the dysferlin gene are depicted in table 1 and ﬁgure 1. As
previously reported, no mutational hot spots were evident, and
mutations were spread widely throughout the gene.
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Research paperCreatine kinase analysis
Creatine kinase (CK) levels were increased in all patients.
Median CK levels were 7000 iU/l (range 300e19000, normal
<150 iU/l) at a median disease duration of 8 years (range
0.5e42 years).
Patient data
Clinical data were available from 36 patients from 32 families (18
men and 18 women); data on current functional status were
available in 30 patients. One patient with one mutation detected
only was believed to present as a symptomatic carrier (patient No
12b)asheisthebrotherofpatientNo12ainwhomtwocompound
heterozygous mutations were found. The ethnic origin of the
patients was somewhat variable: 78% (28 patients) Caucasian
(northern European descent), 17% of patients (six patients) from
India/Pakistan and 5% (two patients) were of Arabic descent.
The phenotype at presentation was identiﬁed from the
patients’ history. Sixty-one per cent of patients (22 patients)
initially presented with LGMD2B (initial symptoms were
proximal lower limb weakness), 11 patients with a Miyoshi
phenotype (difﬁculties standing on tip toes), one patient
presented with proximodistal mode of onset and one patient
was unique in presenting with muscle stiffness after exercise.
Median age of onset was 20 years (range 7e73 years) and the
majority (44%) of patients presented in early adulthood
(between 19 and 27 years of age) (ﬁgure 2). However, 25% of
patients (nine patients) became symptomatic before the age of
13 years. In this group of young patients there was an equal
distribution of those patients who were sporty before onset and
those who were not (four not sporty and ﬁve sporty). At the
other end of the spectrum, one patient presented in her eighth
decade with muscle stiffness rather than weakness.
26 This
patient had always been a keen dancer.
Symptoms at onset
Proximal lower limb weakness in the LGMD2B phenotype and
difﬁculty in toe walking in MM were present in 100% of
patients in those groups. Most patients were characterised by
a slowly progressive onset of weakness (86% in LGMD2B and
64% in MM). Three women became symptomatic shortly after
pregnancy (two with LGMD2B and one with MM), presenting
with a more acute onset of weakness. This is a novel ﬁnding as
we are not aware of any reported patients in whom a possible
Figure 1 Molecular analysis of
patients studied. (A) Relative frequency
of different types of DYSF gene
mutations. (B) Localisation of different
mutation within the DYSF gene.
Numbers represent patients according
to table 2. TM, transmembrane domain.
Figure 2 Distribution of age of onset in the patients studied. Twenty-
ﬁve per cent of patients had symptoms before the age of 13 years.
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disease (table 2).
Clinical onset of the disease was similar within the same
family with respect to age of onset and presenting phenotype.
We did not observe different phenotypes within one family.
However, the number of families studied compared with
sporadic cases was small (four familial cases).
Muscle function
A detailedassessment ofskeletalmusclefunction was available in
21 patients (ﬁgure 3). Median length of disease duration at
assessment was 9 years (range 2.5e42 years). The ﬁndings reﬂect
disease progression with an overlap of proximal and distal weak-
ness at the time of assessment corroborating that although the
diseases may initially present as distinct phenotypes, they largely
overlap in later stages. Plantar ﬂexion, hip adduction and hip
extension were the weakest muscle groups tested. Hand muscles
were relatively well preserved, and scapular winging and
contractures were not common features. Asymmetric muscle
involvement/wasting was noted in three MM patients but not in
LGMD2B. A highly statistically signiﬁcant ﬁnding was a more
pronounced involvement of the lower limbs in comparison with
theupperlimbs(p¼0.00007)inourpatients.Comparisonofupper
and lower limb muscle groups revealed that power was decreased
to 76% (64%) in the upper limbs compared with 49% (65%) in
thelowerlimbsinourpatientcohortenablingrelativelypreserved
muscle function in the arms and hands. Five patients were
wheelchair dependent and one patient required intermittent
wheelchair use (table 3). Four of these patients initially presented
with an LGMD2B and two patients with an MM phenotype.
Pulmonary and cardiac function
Respiratory vital capacity was not reduced to a clinically rele-
vant level in any of the patients nor did any of the patients
report symptoms compatible with nocturnal hypoventilation.
Although not formally assessed, none of the patients has
presented with clinically overt cardiovascular symptoms so far,
with the longest disease duration being 42 years.
Pre-symptomatic muscle function
As anecdotal evidence has previously suggested good muscle
prowess before onset of symptoms in patients affected by
dysferlin deﬁciency, a detailed history was takenin all patients on
theirsportingandphysicalactivitiesandcapabilitiespriortoonset
of symptoms. Fifty-three per cent of dysferlin deﬁcient patients
reported a high degree of activity and were remarkably sporty.No
statisticallysigniﬁcantdifferencewasnotedregardingageofonset
between the group of patients with marked sportiness in
comparison with those who were average or not good at sports
(p¼0.77). It is difﬁcult to provide a direct comparison with
another diagnostic groups on this point. However, when we
addressed the same question in a group of 22 LGMD2A patients,
only9%reportedgoodmuscleprowessbeforeonsetofsymptoms.
No statistically signiﬁcantdifference betweenMM andLGMD2B
was found with respect to pre-symptomatic ﬁtness levels,
suggesting that this parameter is not associated with a speciﬁc
phenotype of dysferlin deﬁciency at presentation.
DISCUSSION
In this ﬁrst UK study of patients affected by dysferlinopathy, we
observed that a subgroup of patients had an earlier age of onset
than previously reported with 25% of patients manifesting
before the age of 13 years. No other factors were identiﬁed
distinguishing this group from the rest of the patients (muta-
tion, pathology data, levels of physical activity prior to onset).
In addition, one previously reported patient showed ﬁrst
symptoms at the age of 73 years which is the oldest age of
disease manifestation reported so far.
26 Taken together, these
data highlight a wider range of age of onset than previously
recognised
468and stress the fact that dysferlinopathy needs to
be considered as a differential diagnosis in children presenting
with limb girdle weakness or a distal myopathy, and that
Figure 3 Muscle strength. The
weakest muscle functions after median
disease duration of 9 years were plantar
ﬂexion, hip adduction and hip extension.
Table 2 Description of symptoms at initial presentation of the disease
All
patients LGMD MM
p Value No % No % No %
Difﬁculty standing on tip toes 8 22 0 0 8 73 0.000012
Proximal lower limb weakness 22 61 22 100 0 0 <0.000005
Weakness acute onset 5 14 3 14 4 36 0.19
Weakness non-acute onset 26 72 19 86 7 64 0.19
Calf wasting (asymmetric) 3 8 0 0 3 27 0.03
Muscle pain 3 8 1 5 2 18 0.25
Muscle stiffness 1 3 0 0 0 0
Pregnancy as possible trigger 3 8 2 9 1 9 1
Statistical signiﬁcance was analysed comparing the two groups of patients with respect to
the amount of patients within one group.
LGMD, limb girdle muscular dystrophy; MM, Miyoshi myopathy.
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advanced age. This broad range of age at onset is further
supported by a recent report of two siblings with dysferlin
deﬁciency presenting with congenital onset.
27
More than half of our patients (53%) described a high degree
of sportiness prior to onset of symptoms. This ﬁnding appears to
be more common in dysferlin deﬁciency as this is not a feature
regularly associated with any other form of muscular dystrophy
known to date. Direct clinical comparison of different forms of
muscular dystrophy is difﬁcult and always represents
a compromise as there is no direct match between age of onset,
clinical presentation and severity. However, we compared our
ﬁndings in dysferlin deﬁcient patients to patients affected by
LGMD2A. In contrast with patients affected by dysferlin deﬁ-
ciency, the majority of calpain deﬁcient patients showed
impairment of muscle function before the onset of overt
weakness as they were signiﬁcantly more often not good at
sports/slow or avoided sports altogether before disease onset.
The factor(s) responsible for this ‘sporty’ phenotype in dysferlin
deﬁciency are unknown, but this ﬁnding suggests that these
patients may not only have normal/preserved muscle function
but may actually have very good muscle function prior to onset
of wasting and weakness. Impaired sarcolemmal resealing of
damaged myoﬁbres has been identiﬁed as a key patho-
mechanism leading to muscular dystrophy in the dysferlin
knockout mouse.
12 But this mechanism cannot conclusively
explain why dysferlin deﬁcient patients exhibit good muscle
prowess before onset of weakness and wasting. An exaggerated
turnover of satellite cells at an early stage of the disease could
potentially contribute to this phenotype but this possibility has
not been investigated so far.
Although the same mutation may lead to initial presentation
as MM or LGMD2B even within the same family,
28 29 we did
not observe this degree of intrafamilial variability in our cohort
of patients.
30 In contrast with a recent study,
4 most of our
patients did present with either proximal or distal onset and
only one patient displayed proximal and distal involvement
simultaneously, although with disease progression we noted as
have others that it was difﬁcult to distinguish those who had
initially presented with proximal or distal involvement. The
larger number of patients with proximal presentation in our
study may also reﬂect a referral bias as our diagnostic service is
primarily orientated towards the LGMDs. We did not identify
any patient presenting with distal anterior involvement,
3 similar
to the observation by Nguyen et al,
4 suggesting that this appears
to be a rare presentation of dysferlinopathy.
The muscle most severely affected in our group of patients
was the gastrocnemius muscle leading to an inability to stand on
tiptoes also in patients initially presenting with a limb girdle
phenotype. This has to take into account that the median
disease duration at muscle assessment was 9 years (range
2.5e42 years). Overall weakness appears to be more pronounced
in the lower than the upper limbs.
Two patients developed symptoms shortly after delivery of
their ﬁrst child, and one patient after delivery of her third child
which to our knowledge has not been reported in dysferlin
deﬁciency so far. This may suggest that pregnancy could
possibly trigger onset of symptoms.
Mutations were spread along the entire gene, corroborating
the ﬁndings that no mutational hot spots exist in the dysferlin
gene (ﬁgure 1).
7 In addition, our ﬁndings are in line with most
previous reports in that we did not ﬁnd any genotypeepheno-
type correlation either with regard to the nature of the mutation
and severity or with the phenotype and age at presentation. In
agreement with most data published so far but in contrast with
a recently published study,
11 we could not ﬁnd a correlation
between residual amounts of dysferlin on western blotting or
immunohistochemistry and the resulting phenotype.
Recently, two patients have been reported as symptomatic
dysferlin gene mutation carriers with heterozygous missense
mutations in exons 18 and 20, respectively.
31 Similarly, the
brother of patient 12a who is affected by LGMD2B based on
a compound heterozygous mutation in the dysferlin gene
appears to be a symptomatic carrier with no second mutation
detected (patient 12b). His mutated allele was maternally
inherited (truncating mutation/deletion, exon 8). He presented
later in life than his brother and symptoms were less severe with
pain in his legs and prolonged recovery time after exercise
without overt muscle weakness. His serum CK was slightly
raised (300 IU, normal <130 IU), and the muscle biopsy showed
myopathic features and patchy dysferlin labelling at the sarco-
lemma on immunohistochemistry similar to the two previously
reported symptomatic carriers.
31 Although dysferlin and calpain
3 appeared normal on western blot, it is highly likely that the
clinical and biochemical ﬁndings are based on the single trun-
cating mutation in exon 8 of the dysferlin gene in this patient.
Taken together, the data presented in this study extend our
knowledge on the phenotype of dysferlinopathy as age of onset
may be broader than previously appreciated reaching from child-
hoodtolateinlife.Furthermore,goodmuscleprowessbeforeonset
of weakness appears a common ﬁnding in this form of muscle
disease,understandingofwhichmaycontributetotheelucidation
of the underlying pathogenetic mechanisms in dysferlinopathy.
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